Prospective Study of Palonosetron in Radiation Induced Nausea and Vomiting (RINV)
Status:
Completed
Trial end date:
2017-08-07
Target enrollment:
Participant gender:
Summary
This phase II study will investigate the use of palonosetron in the efficacy of prophylaxis
or rescue of single or multiple fraction radiation induced nausea and vomiting. This
prospective study employs a parallel arm design, allowing for inclusion of patients with
pre-existing nausea and vomiting versus no current nausea or vomiting. Eligible patients
receiving radiotherapy known to have a low or moderate emetogenic risk will receive every
other day dosing of 0.5 mg palonosetron for the length of treatment. Nausea, vomiting, use of
rescue medication, and impact on quality of life will be monitored during and after radiation
treatment completion.